Oculis Holding AG Announces First Patient Enrolled In LEOPARD, An Investigator-Initiated Trial, With OCS-01 Eye Drops For The Treatment Of Cystoid Macular Edema
Portfolio Pulse from Happy Mohamed
Oculis Holding AG (NASDAQ:OCS) has enrolled the first patient in the LEOPARD trial, which will evaluate the potential of OCS-01 eye drops for the treatment of cystoid macular edema (CME). The trial follows positive data from the Stage 1 Phase 3 DIAMOND trial in patients with Diabetic Macular Edema (DME). CME is a significant cause of vision loss after ocular surgery, affecting approximately 28% of patients who undergo such procedures.
August 04, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oculis' initiation of the LEOPARD trial for OCS-01 eye drops could potentially open up a new treatment avenue for CME, a significant cause of vision loss. This follows positive data from the DIAMOND trial in DME patients.
The initiation of the LEOPARD trial indicates progress in Oculis' product development, which could potentially lead to a new treatment for CME. This is likely to be viewed positively by investors, given the positive data from the DIAMOND trial in DME patients. Therefore, this news could potentially have a positive impact on Oculis' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100